Kyverna Therapeutics (KYTX) Other financing activities (2023 - 2026)
Kyverna Therapeutics posted quarterly Other financing activities of $69000.0 for Q1 2026, down 9.21% year-on-year from $76000.0 in Q1 2025, and up 9.52% on a QoQ basis from $63000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Other financing activities data on file, last reported at $69000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities fell 9.21% year-over-year to $69000.0; the trailing twelve-month figure through Mar 2026 stood at $468000.0 (down 2.9% YoY), and the FY2025 full-year result was $475000.0, down 85.87% from the prior year.
- Other financing activities for Q1 2026 stood at $69000.0, up from $63000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $3.0 million in Q1 2024 and bottomed at $63000.0 in Q4 2025.
- The 4-year median for Other financing activities is $336000.0 (2025), against an average of $770714.3.
- The widest annual swing landed in 2025, when Other financing activities sank 97.43%; it then slipped 9.21% in 2026.
- A 4-year view of Other financing activities shows it stood at $1.5 million in 2023, then plunged by 72.75% to $406000.0 in 2024, then sank by 84.48% to $63000.0 in 2025, then grew by 9.52% to $69000.0 in 2026.
- The last three Other financing activities figures came in at $69000.0 (Q1 2026), $63000.0 (Q4 2025), and $336000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Jun 30, 2025 | 336,000.00 |
| Jun 30, 2025 | 336,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Jun 30, 2024 | 406,000.00 |
| Jun 30, 2024 | 406,000.00 |
| Mar 31, 2024 | 2.96 Mn |
| Mar 31, 2024 | 2.96 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Dec 31, 2023 | 1.49 Mn |